Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Hung-Wei WangHsueh-Chou LaiTsung-Hui HuWen-Pang SuSheng-Nan LuChia-Hsin LinChao-Hung HungPo-Heng ChuangJing-Houng WangMei-Hsuan LeeChien-Hung ChenCheng-Yuan PengPublished in: Journal of gastroenterology and hepatology (2018)
The mFIB-4 index alone or in combination with DM is the optimal noninvasive predictor of HCC risk in CHB patients receiving entecavir therapy.